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p53 is frequently wild type (wt) in diffuse large B-cell lymphoma
(DLBCL) associated with t(14;18)(q32;q21) that overexpresses
BCL2. Nutlin-3a is a small molecule that activates the p53
pathway by disrupting p53–MDM2 interaction. We show that
nutlin-3a activates p53 in DLBCL cells associated with
t(14;18)(q32;q21), BCL2 overexpression and wt p53, resulting
in cell cycle arrest and apoptosis. Nutlin-3a treatment had
similar effects on DLBCL cells of activated B-cell phenotype
with wt p53. Cell cycle arrest was associated with upregulation
of p21. Nutlin-3a-induced apoptosis was accompanied by BAX
and PUMA upregulation, BCL-XL downregulation, serine-70
dephosphorylation of BCL2, direct binding of BCL2 by p53,
caspase-9 upregulation and caspase-3 cleavage. Cell death was
reduced when p53-dependent transactivation activity was
inhibited by piﬁthrin-a (PFT-a), or PFT-l inhibited direct p53
targeting of mitochondria. Nutlin-3a sensitized activation of the
intrinsic apoptotic pathway by BCL2 inhibitors in t(14;18)-
positive DLBCL cells with wt p53, and enhanced doxorubicin
cytotoxicity against t(14;18)-positive DLBCL cells with wt
or mutant p53, the latter in part via p73 upregulation. Nutlin-
3a treatment in a xenograft animal lymphoma model inhibited
growth of t(14;18)-positive DLBCL tumors, associated with
increased apoptosis and decreased proliferation. These data
suggest that disruption of the p53–MDM2 interaction by nutlin-
3a offers a novel therapeutic approach for DLBCL associated
with t(14;18)(q32;q21).
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Introduction
The t(14;18)(q32;q21) resulting in overexpression of the
antiapoptotic protein BCL2 is a hallmark of follicular lymphoma
(FL).
1 This translocation is also present in a subset of diffuse large
B-cell lymphoma (DLBCL) tumors, thought to be closely related
to or transformed from FL.
2 The t(14;18), by upregulating BCL2
expression and therefore BCL2-mediated resistance to apoptotic
stimuli, is regarded as an initiating oncogenic event in FL,
although genetically manipulated animal models have shown
that additional genetic events are necessary for lymphoma
development.
3,4 Additional genetic events are most certainly
involved in transformation of FL to DLBCL.
1
The signaling pathway regulated by the tumor suppressor
gene p53 is inactivated in most cancers, half of which harbor
p53 gene mutations.
5 In vitro and in vivo studies have shown,
however, that reactivation of p53, either by genetic manipula-
tion or by application of small molecules that speciﬁcally target
the p53 pathway, can result in the elimination of tumors
initiated by transforming events independent of p53.
6,7 Accord-
ingly, recent studies have shown that inhibition of MDM2, a
critical negative regulator of p53, by using the recently
developed small-molecule nutlin-3a results in signiﬁcant anti-
tumor activity in various malignancies, including hematopoietic
tumors harboring a wild-type (wt) p53 gene.
8–21
p53 mutations are rare in FLs, but, when present, likely have a
pathogenetic role in transformation to DLBCL.
3,22,23 Several
studies also have implicated disruption of p53/MDM2 signaling
axis in transformation of FL to DLBCL. For example, Sander
et al.
24 used immunohistochemical and sequencing analysis to
show that FLs typically do not overexpress p53 protein, whereas
30% of FLs that transformed to DLBCL overexpressed p53, most
of which also had p53 gene mutation. Moller et al.
25 showed
p53 gene mutations and MDM2 overexpression in 22 and 43%
of DLBCLs, respectively. Furthermore, decreased levels of
p19ARF, a product of the CDKNA gene and a negative regulator
of MDM2, were observed in DLBCLs, either because
of homozygous deletion or promoter hypermethylation, in
approximately 10–20% of tumors. In aggregate, 62% of DLBCL
tumors had aberrations.
25 In a comprehensive study of 91 tumor
specimens from 29 patients with FL who had transformed to
DLBCL, 82% of tumors with mutated p53 were immunopositive
for p53, whereas 71% of tumors with wt p53 showed no p53
expression. p53 gene mutations were observed in 28%
of transformed tumor samples, but were not observed in FL at
diagnosis. High expression of MDM2 was observed in sequen-
tial pre- and posttransformation samples and did not correlate
with mutational status of p53, indicating a p53-independent
mechanism. This study not only conﬁrmed the importance of
p53 mutation in the process of transformation but also identiﬁed
increased expression of MDM2 as a major event in transforma-
tion that could be targeted for therapy.
26
In this study, we investigated the in vitro and in vivo antitumor
potential of nutlin-3a, a functional inhibitor of MDM2 against
DLBCL associated with t(14;18)(q32;q21), and whether nutlin-
3a-mediated activation of the p53 pathway can overcome the
antiapoptotic action of overexpressed BCL2 as a result of
t(14;18)(q32;q21). By using an in vitro system with cultured
t(14;18)-positive DLBCL cells, or a xenograft lymphoma animal
model, our data show that nutlin-3a can activate the p53
pathway inducing cell cycle arrest and apoptosis in t(14;18)-
positive DLBCL cells with wt p53, overcoming BCL2
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augmenting activation of the intrinsic apoptotic pathway in
t(14;18)-positive DLBCL cells induced by BH3 mimetic mole-
cules targeting directly the mitochondria. In addition, nutlin-3a
enhanced the activity of classical chemotherapeutic agents
(for example, doxorubicin) against DLBCL cells associated with
t(14;18) that harbor mutated p53, in part, through activation of
p73. In sum, we provide evidence that MDM2 antagonists can
be part of a therapeutic strategy for patients with DLBCL
associated with t(14;18)(q32;q21).
Materials and methods
Cell lines and reagents
Six DLBCL cell lines of germinal center type harboring
t(14;18)(p32;q21) and overexpressing BCL2 were used, includ-
ing DoHH2, MCA and EJ, harboring a wt p53 gene, and Pfeiffer,
MS and BJAB with mutated p53. DoHH2 and Pfeiffer (DLBCL)
cells were obtained originally from DSMZ, (Braunschweig,
Germany) and ATCC (Manassas, VA, USA), respectively. MS, EJ
and MCA (DLBCL) cell lines were established at MD Anderson
Cancer Center (by RJF).
27 Two DLBCL cell lines with wt p53 and
of activated B-cell (ABC) type, OCI-LY3 (with BCL2 gene
ampliﬁcation) and OCI-LY10 were also used. All cells were
maintained in RPMI 1640 medium supplemented with 15% fetal
bovine serum (Invitrogen, Grand Island, NY, USA),
at 371C, in a humidiﬁed atmosphere containing 5% CO2.
A number of molecules were added to cell cultures in
different concentrations as indicated including nutlin-3a, a
selective small-molecule antagonist of MDM2 (Calbiochem,
San Diego, CA, USA); piﬁthrin-a (PFT-a), an inhibitor of
p53-dependent transactivation of p53-responsive genes; PFT-m,
an inhibitor of p53 translocation to mitochondria; YC-137, a
BH3-mimetic; and the chemotherapeutic agent doxorubicin (all
from Calbiochem). All experiments were repeated at least twice.
Reverse-transcription PCR and direct sequencing of
p53 cDNA
Total RNA extraction, synthesis of cDNA, ampliﬁcation of the
entire open reading frame of p53 gene by PCR and sequencing
were performed as previously described.
12
Colony formation and MTS assays
Colony formation in methylcellulose (Sigma, St Louis, MO, USA)
was performed according to the manufacturer’s instructions.
Brieﬂy, 500 cells in 300ml of methylcellulose solution were
treated with 2, 5 and 10mg/ml of nutlin-3a or an equivalent
amount of dimethyl sulfoxide, and then plated and incubated for 2
weeks. The wells were stained with p-iodonitrotetrazolium violet
(Sigma), and colonies were counted using a stereomicroscope.
Cells were treated with nutlin-3a in 96-well plates.
A tetrazolium compound (MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium))
was then added to each well, and the number of viable cells was
quantiﬁed using the CellTiter 96 AQueous cell proliferation assay
(Promega, Madison, WI, USA) and mQuant spectrophotometer
(BIO-TEK Instruments, Winooski, VT, USA) according to the
manufacturer’s instructions.
Cell cycle analysis
Cells were ﬁxed overnight in ice-cold ethanol (70% volume/
volume), and stained for 30min with propidium iodide solution
(50mg/ml propidium iodide, 200U/ml DNase-free RNase in
phosphate buffer solution, pH 7.4; Roche Applied Science,
Indianapolis, IN, USA) at 371C. DNA content was determined
using a FACS Calibur ﬂow cytometer (Becton Dickinson
Immunocytometry Systems, San Jose, CA, USA) and the cell
cycle was analyzed using ModFit LT software (Verity Software
House, Topsham, ME, USA).
Cell viability and apoptosis studies
Cell viability was evaluated using trypan blue exclusion cell
counts in triplicate. Annexin V staining (BD Biosciences
Pharmingen, San Diego, CA, USA) detected by ﬂow cytometry
was used to assess apoptosis according to the manufacturer’s
instructions. Brieﬂy, the cells were washed in ice-cold
phosphate-buffered saline and resuspended in binding buffer
at a concentration of 1 10
6 cells/ml. Aliquots of 100mlo f
1 10
5 cells/ml were incubated with 2ml annexin V–ﬂuorescein
isothiocyanate for 15min, followed by 5ml propidium iodide for
1min in dark at room temperature. In all, 1 10
4 ungated cells
were then counted using a FACS Calibur ﬂow cytometer (Becton
Dickinson). Also, cytospin preparations of nutlin-3a-treated cells
were stained with 4’,6-diamidino-2-phenylindole and examined
by ﬂuorescence microscopy for morphological evidence of
apoptosis. Control cells were included in each set of experiments.
Western blot and coimmunoprecipitation studies
Western blot analysis was performed as previously described.
28
Antibodies used included: p53, p21, BCL2 and BAX (Dako,
Carpinteria, CA, USA);
Ser15p-p53, PUMA,
Ser70p-BCL2, caspase-
3 and cleaved caspase-9 (Cell Signaling Technology, Beverly,
MA, USA); BCL-XL (Zymed, South San Francisco, CA, USA);
activated caspase-3 (BD Biosciences Pharmingen); MDM2, and
p73a (Santa Cruz Biotechnology, Santa Cruz, CA, USA); MDMX
(Bethyl, San Antonio, TX, USA); and b-actin (control for protein
load; Sigma). Also, coimmunoprecipitation of cell lysates
prepared in 1% CHAPS extraction buffer was performed as
previously described with slight modiﬁcations, using anti-BCL2
(rabbit monoclonal, Cell Signaling Technology).
28 Immunocom-
plexes were analyzed by western blot analysis using anti-p53 and
anti-BCL2 (mouse monoclonal, DAKO).
Immunoﬂuorescence
Immunoﬂuorescence was performed as previously described.
12
The primary anti-p53 antibody (mouse monoclonal from Dako)
was applied overnight at 41C and the immunoreaction was
detected with Alexa Fluor 488 goat anti-mouse secondary
antibody (Molecular Probes, Invitrogen). The 4’,6-diamidino-2-
phenylindole was used as counterstain. Staining of cells omitting
the primary antibody step served as a negative control.
Human tumor xenografts
A total of 14 female severe combined immunodeﬁciency/beige
mice (4- to 6-week old) were obtained from Taconic (New York,
NY, USA) and maintained under speciﬁc pathogen-free condi-
tions. Mice were injected subcutaneously with 10 10
6 DoHH2
cells and divided randomly in two equal treatment groups.
Treatment was started intraperitoneally after the tumors were
established (that is, palpable). Nutlin-3a (25mg/kg, Alexis
Biochemicals, San Diego, CA, USA) or the vehicle control was
administered daily for a period of 14 days (14 doses). Weight of
the mice was measured twice per week. Tumor volumes were
measured daily with a caliper and calculated using the formula
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LeukemiaV¼width height depth/2. For western blotting, histological
and immunohistochemical analyses, tumors (three from each
group, after three injections) were snap frozen or ﬁxed in 10%
formalin solution and processed routinely. Immunohistochem-
ical analysis and TUNEL (terminal deoxynucleotidyl transferase
dUTP nick end labeling) were performed as previously
described. All animal studies were conducted in accordance
with the guidelines of MD Anderson Cancer Center.
Statistical analysis
For evaluating the additive, synergistic or antagonistic effects of
different agents, a combination index (CI) was calculated using
the Calcusyn Software (Biosoft, Ferguson, MO, USA), according
to the Chou–Taladay method. For comparing tumor sizes, p21,
Ki-67 and activated caspase-3 immunohistochemical ﬁndings
and apoptotic indexes (TUNEL), the non-parametric Mann–
Whitney U-test and Statview program (Abacus Concepts,
Berkeley, CA, USA) were used.
Results
Expression and mutation status of p53 in DLBCL cells
To investigate the mutation status of the p53 gene and
expression levels of p53 protein in the DLBCL cell lines,
western blot analysis was performed. As shown in Figure 1a, low
levels of p53 were seen in DoHH2 and MCA in comparison
with MS cells. No p53 protein was detected in Pfeiffer cells. In a
separate western blot analysis, EJ, OCI-LY3 and OCI-LY10 cells
showed lower levels of p53 than BJAB cells. Direct sequencing
of the entire open reading frame of the p53 gene showed that
DoHH2, MCA, OCI-LY3 and OCI-LY10 cells harbor wt p53.I n
MS cells, a non-functional missense mutation (TAC (tyr) to CAC
(his)) at codon 234 of exon 7 in the DNA-binding domain of p53
was identiﬁed. In BJAB cells, a non-functional missense mutation
(CAT (his) to CGT (arg) at codon 578 of exon 6 was identiﬁed. We
could not amplify a p53 product in Pfeiffer cells, possibly because
of a gross deletion, as suggested also by western blot analysis.
Nutlin-3a inhibits the growth of DLBCL cells depending
on p53 mutation status
To investigate the functional status of the p53 pathway, the cell
lines were treated with nutlin-3a. Treatment with nutlin-3a
showed remarkable antiproliferative activity against DoHH2, EJ
and MCA cells (with wt p53), but not against MS, BJAB and
Pfeiffer cells (with mutant (mt) p53). MTS assay at 48h after
incubation with 10mM of nutlin-3a showed that growth of
DoHH2 and MCA cells was inhibited by 85 and 89%,
respectively (Figure 1b). Similarly, treatment with nutlin-3a also
decreased cell proliferation of OCI-LY3 and OCI-LY10 cells,
both of ABC type with wt p53 (Figure 1b). More importantly,
nutlin-3a treatment resulted in a dose-dependent decrease of the
colony-forming ability of DoHH2, MCA, OCI-LY3 and EJ cells,
whereas no appreciable effect was observed on Pfeiffer, BJAB
and MS cells up to a concentration of 10mM (Figure 1b). The
colony-forming assay is not contributory for OCI-LY10 cells,
as they lack the colony-forming ability in methylcellulose.
Nutlin-3a induces cell cycle arrest in t(14;18)-positive
DLBCL cells through activation of the p53 pathway and
upregulation of p21
To investigate the effects of p53 activation on cell cycle
progression, we analyzed the cell cycle. Nutlin-3a treatment
of DLBCL cells associated with t(14;18) and harboring wt p53
showed a substantially reduced S-phase fraction (Figure 2a). At
24h after treatment with 2mM of nutlin-3a, the S-phase fraction
of DoHH2 and MCA cells decreased by B80 and 85%,
respectively. In DoHH2 cells, an increase in G1- and G2/M-
phase fractions was observed, indicating cell cycle arrest at the
G1 and G2/M checkpoints. Under similar treatment conditions,
an increase of the G1 phase along with an increase of the sub-
G1-phase fraction (indicator of cell death) was observed in
MCA, indicating both cell cycle arrest in G1 phase and cell
death. However, treatment of EJ cells with 2mm nutlin-3a
resulted only in an increased sub-G1 fraction without any
change in any other phases of the cell cycle. This result indicates
cell death, without any arrest in either G1– or G2–M phase.
Treatment of OCI-LY3 cells with 2mm nutlin-3a resulted in
increases of the G1- and sub-G1 phases along with a decreased
S-phase fraction, indicating both cell cycle arrest in G1 phase
and cell death (Figure 2a). However, similar treatment of OCI-
LY10 cells resulted predominantly in induction of cell death, as
evident by the considerable increase of the sub-G1 phase. No
cell cycle arrest in G1– or G2–M phase or decrease of S phase
was observed (Figure 2a). In contrast, in t(14;18)-positive DLBCL
cell lines with mt p53 (Pfeiffer, MS or BJAB), neither cell cycle
arrest nor apoptotic cell death was observed with nutlin-3a
treatment at any concentration (Figure 2a).
Western blot analysis showed stabilization of wt p53 protein
levels in DoHH2, MCA, OCI-LY3, OCI-LY10 and EJ cells on
treatment with nutlin-3a, whereas no such effects were seen in
BJAB and MS cells, both with mt p53 (Figure 2b). The cyclin-
dependent kinase inhibitor p21, a known transcriptional target of
p53, showed increased levels, indicating that stabilized wt p53 is
functional and capable of inducing p21 expression (Figure 2b).
Increased p53 protein levels were also shown by immunoﬂuor-
escence in nutlin-3a-treated cells with wt p53 (Figure 2c).
Nutlin-3a induces apoptotic cell death in t(14;18)-
positive DLBCL cells as well as DLBCL cells of ABC type
through activation of the p53 apoptotic pathway
To investigate the nature of nutlin-3a-induced suppression of
cell viability, annexin V staining and ﬂow cytometry were
performed. As illustrated in Figure 3a, there was a concentra-
tion-dependent increase in annexin V binding in DoHH2, MCA,
EJ, OCI-LY3 and OCI-LY10 cells, but not in Pfeiffer, MS and
BJAB cells. At 24h following treatment with 10mM of nutlin-3a,
annexin V binding was increased by B80, 74 and 58% in
DoHH2, MCA and EJ cells, respectively. In OCI-LY3 and OCI-
LY10 cells, annexin V binding was increased by 63 and 74%,
respectively. No signiﬁcant increase in annexin V binding was
observed in nutlin-3a-treated Pfeiffer, BJAB and MS cells that
harbor mt p53 (Figure 3a). Also, 4’,6-diamidino-2-phenylindole
staining and ﬂuorescence microscopy demonstrated nuclear
condensation and fragmentation, morphologic evidence of
apoptotic cell death, in nutlin-3a-treated wt p53 cells (Figure 3b).
To examine the possible mechanisms underlying nutlin-3a-
mediated cell death, western blot analysis was performed.
As shown in Figure 3c, alterations in the levels of pro- and
antiapoptotic proteins involved in the intrinsic apoptotic path-
way were detected in nutlin-3a-treated DLBCL cells. Speciﬁ-
cally, an increase of the proapoptotic proteins BAX and PUMA,
both transcriptional targets of p53, was observed in DoHH2,
MCA and EJ cells (wt p53) at 24h after nutlin-3a treatment.
In ABC-DLBCL cell lines, BAX was increased in both OCI-LY3
and OCI-LY10 cells, whereas PUMA level was increased only in
OCI-LY3 cells (Figure 3c). Also, levels of the antiapoptotic
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Leukemiaprotein BCL-XL were decreased in DOHH2, MCA and OCI-
LY10 cells, but not in OCI-LY3 and EJ, whereas the levels of
BCL2 remained almost constant in these cell lines (Figure 3c).
Because the antiapoptotic activity of BCL2 is dependent not only
on protein levels but also on the its phosphorylation status, we
also examined
p-Ser70BCL2 levels.
29,30 All DLBCL cell lines with
wt p53 (DoHH2, MCA, OCI-LY10, OCI-LY3 and EJ) showed
a signiﬁcant decrease of
p-Ser70BCL2 levels after nutlin-3a
treatment. In contrast, these changes were not observed in
nutlin-3a-treated Pfeiffer, BJAB and MS cells with mt p53
(Figure 3c).
In addition to enhancing the antiapoptotic activity of BCL2,
serine-70 phosphorylation of BCL2 has been shown to inhibit the
interaction of p53 with BCL2, one of the transcription-indepen-
dent mechanisms of p53-mediated proapoptotic functions.
For this reason, we investigated whether nutlin-3a-induced cell
death is associated with physical interaction of the p53 and BCL2
proteins.
31 Coimmunoprecipitation studies showed that nutlin-3a
treatment induced binding of BCL2 by p53 in DoHH2 cells and
to a lesser degree in MCA cells (Figure 3d).
To further elaborate on the apoptotic mechanisms, and clarify
the functional importance of the changes associated with
Mt p53 Mt p53 Wt p53
MDM2
p53
β-actin
BCL2
Mt p53
100
MS
80
MCA
DoHH2
OCI-LY3
EJ
60
40
Pfeiffer
OCI-LY10
BJAB
20
0
%
 
R
e
l
a
t
i
v
e
 
t
o
 
C
o
n
t
r
o
l
C
e
l
l
 
G
r
o
w
t
h
Wt p53
MS
OCI-LY3
Pfeiffer
M
t
 
p
5
3 MCA
DoHH2
W
t
 
p
5
3
BJAB
Nutlin-3a (M)
Nutlin-3a ( 025 1 0 M)
EJ
MS Pfeiffer BJAB OCI-Ly3 MCA DoHH2 EJ
60
80
100
60
80
100
%
 
R
e
l
a
t
i
v
e
 
t
o
C
o
n
t
r
o
l
C
o
l
o
n
i
e
s
0
20
40
0
20
40
Wt p53
10 5 2 0
Nutlin-3a 10 5 2 0
Nutlin-3a (M) 10 5 2 0
(M) 10 5 2 0 (M)
Figure 1 Nutlin-3a inhibits the growth of diffuse large B-cell lymphoma (DLBCL) cell lines associated with t(14;18)(q32;q21), depending on the
presence or absence of p53 mutation. (a) p53 expression levels were assessed in six DLBCL associated with t(14;18) cell lines and two DLBCL cell
lines of activated B-cell type using western blot analysis. Immunoblots showed high levels of p53 in MS and BJAB, whereas DoHH2, MCA, EJ,
OCI-LY3 and OCI-LY10 expressed comparatively lower levels. No p53 protein was observed in Pfeiffer cells. MDM2 protein levels are also shown.
These data suggested that p53 might be mutated in BJAB and MCA, deleted in Pfeiffer and unmutated (wild type, wt) in the remaining cell lines.
This was veriﬁed by ampliﬁcation of p53 cDNA and direct sequencing of the entire open reading frame of p53 in these cells. (b) MTS (3-(4,
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay after 48h showed dose-dependent decrease of cell
viability on treatment with nutlin-3a in cell lines with wt p53, whereas no loss of cell viability was observed in cell lines with mutant (mt) p53.
(c, d) Colony formation assay after treatment with nutlin-3a showed inhibition of growth of cells with wt p53, but not that of MS, BJAB and Pfeiffer
cells, which harbored mt p53. At 2 weeks after treatment, a dose of 2–10mM nutlin-3a completely inhibited the formation of colonies in cells with
wt p53, whereas a dose up to 10mM had no signiﬁcant effect on cells with mt p53.
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Leukemianutlin-3a-induced cell death revealed in our analysis, we studied
the apoptotic effects in nutlin-3a-treated DoHH2 and MCA cells
pretreated with PFT-a, an inhibitor of p53 transcriptional activity,
or PFT-m, an inhibitor of p53 protein translocation to mitochon-
dria.
32,33 As shown in Figure 3e, both PFT-a and PFT-m rescued a
signiﬁcant proportion of nutlin-3a-treated DoHH2 and MCA cells,
suggesting that p53 transcriptional and posttranscriptional
mechanisms involve direct targeting of antiapoptotic proteins by
p53. Interestingly PFT-m rescued a larger proportion of nutlin-3a-
treated DoHH2 cells compared with PFT-a, whereas the opposite
was found for MCA cells, a ﬁnding reﬂected in our western blot
analysis and coimmunoprecipitation data.
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Figure 2 Nutlin-3a induces cell cycle arrest and/or cell death in diffuse large B-cell lymphoma (DLBCL) associated with t(14;18)(q32;q21)
through activation of the p53 pathway. (a) At 24h after treatment with 2mM nutlin-3a in DLBCL cell lines with wild-type (wt) p53 resulted in G1
and G2/M phase cell cycle arrest with decreased S phase (DoHH2), cell cycle arrest in G1 phase, decreased S phase accompanied by cell death
(MCA and OCI-Ly3) or cell death without cell cycle arrest and decreased S phase (OCI-LY10 and EJ). No cell death or cell cycle arrest was seen
in cells that lacked p53 or with mutant p53 (Pfeiffer, MS and BJAB). (b) Western blot analysis at 24h after treatment with 5mM nutlin-3a showed
increased expression of p21, in parallel with increased p53 levels in cells with wt p53 along with upregulation of MDM2 and downregu-
lation of MDMX. No such changes were detected in Pfeiffer, BJAB and MS cells treated with nutlin-3a. (c) At 12h following treatment with
nutlin-3a, DoHH2 and MCA cells had increased levels of p53 visualized by immunoﬂuorescence. p53 localization was predominantly nuclear.
The 4’,6-diamidino-2-phenylindole was used as counterstain of the nuclei.
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LeukemiaIt must be added that although PFT-m was protective at the
higher non-toxic dose of 4.8mM, above 5mM induced signiﬁcant
cell death in both DoHH2 and MCA cells, an unexpected
ﬁnding (data not shown). Similar data have been reported
recently in chronic lymphocytic leukemia cells.
34 Also, in
higher doses, above 8mM, PFT-m induced signiﬁcant cell death
in Pfeiffer and MS cells (mt p53). For comparison, we similarly
assessed ALKþ anaplastic large cell lymphoma cells that did
not show signiﬁcant cytotoxicity up to a concentration of 10mM,
suggesting that this phenomenon is cell-type speciﬁc.
Nutlin-3a sensitizes t(14;18)-positive DLBCL cells with
wt p53 to activation of the intrinsic apoptotic pathway
Following up on our data that showed that nutlin-3a-mediated
activation of p53 affects the intrinsic apoptotic pathway,
we investigated whether nutlin-3a treatment can facilitate
activation of the intrinsic apoptotic pathway mediated by
YC-137, a BH3 mimetic, that directly targets the antiapoptotic
proteins BCL2 and BCL-XL.
35 The results showed that a small
concentration of nutlin-3a dramatically increased the cytotoxi-
city of YC-137, speciﬁcally in cells with wt p53. (Figure 3f).
Furthermore, combining YC-137 and nutlin-3a synergistically
increased cytotoxicity in both DoHH2 and MCA cells (average
CI¼0.53 and CI¼0.35, respectively; Figure 3f).
Nutlin-3a enhances the antiproliferative activity of
chemotherapeutic agents against t(14;18)-positive
DLBCL cells with wt p53
Previous studies have shown that nutlin-3a can enhance the
antitumor activity of standard chemotherapeutic agents against
cells harboring wt p53.
36 To investigate whether this applies to
DLBCL cells associated with t(14;18)(q32;q21), we combined
nutlin-3a and doxorubicin treatment in our in vitro system. As
shown in Figure 4a, treatment of DoHH2 and MCA cells with
nutlin-3a and doxorubicin for 48h showed synergistic antiproli-
ferative activity (average CI¼0.34 and CI¼0.29, respectively).
Nutlin-3a also enhances the antiproliferative activity
of chemotherapeutic agents against DLBCL cells
with mt p53 via p73
As it is known that p53 gene mutation is associated with
progression of FL to DLBCL in a subset of cases, and recent
studies have shown that high doses of nutlin-3a can induce
cytotoxicity of cancer cells harboring mt p53 gene, through
effects on partner proteins of MDM2 other than p53, we
investigated the effect of nutlin-3a on the antitumor activity of
doxorubicin against DLBCL cells harboring mt p53.
37–39 As
shown in Figure 4b, application of 10mM nutlin-3a for 48h had
no effect on the growth and cell viability of MS and Pfeiffer cells.
However, nutlin-3a enhanced the cytotoxicity and inhibitory
effect of 0.5mg/ml of doxorubicin, reducing cell viability in
these cell lines from 70 to 36% and 85 to 35%, respectively, and
reducing cell growth from 78 to 28% and 79 to 19%,
respectively (Figure 4b). Western blot analysis showed that
nutlin-3a combined with a relatively low dose of doxorubicin
induced p73a expression, another MDM2 partner protein.
However, in BJAB cells, combined treatment of doxorubicin
and nutlin-3a did not have a synergistic effect on doxorubicin
cytotoxicity. This may be attributable to the lack of signiﬁcant
induction of p73a expression in BJAB cells after combined
treatment (Figure 4b). The explanation for the lack of effect in
BJAB cells is not clear. In aggregate, the ﬁndings suggest that
combined genotoxic and non-genotoxic treatment may have
effect in DLBCL cells with t(14;18)(q32;q21) and mt p53,
depending on the ability of the combined treatment to
upregulate p73a expression and signaling.
Nutlin-3a treatment inhibits growth of t(14;18)-positive
DLBCL tumors harboring wt p53 in vivo
To further investigate the therapeutic potential of nutlin-3a-
mediated activation of p53, we employed a human xenograft
lymphoma animal model using the DoHH2 cell line. Nutlin-3a
was well tolerated, without signiﬁcant weight loss or other
obvious toxicity signs in severe combined immunodeﬁciency–
beige mice. After two weeks of nutlin-3a treatment of severe
combined immunodeﬁciency–Beige mice with already estab-
lished (palpable) subcutaneous DoHH2 tumors, the mean tumor
volume in the control group was 1965.5mm
3, whereas in the
nutlin-3a-treated group, the mean tumor volume was
107.5mm
3 (Po0.02, Mann–Whitney U-test; Figure 5a). In
addition, two of the nutlin-3a-treated mice had no palpable
tumors at the end of treatment. Western blot analysis of six
tumors (three from each group) after three injections showed
upregulation of p53, and p53 transcriptional targets p21 and
MDM2, speciﬁcally in the nutlin-3a-treated tumors, supporting
Figure 3 Nutlin-3a induces apoptotic cell death of t(14;18)-positive diffuse large B-cell lymphoma (DLBCL) and ABC-type DLBCL cells through
activation of the p53 pathway. (a) At 48h after incubation with 10mM nutlin-3a, a considerable increase in annexin V binding was observed in DLBCL
cells with wild-type (wt) p53, indicating apoptotic cell death. No signiﬁcant change was observed in Pfeiffer, BJAB and MS cells, which have mutant
p53 (left panel). Annexin V binding corresponding to various concentrations of nutlin-3a treatment is depicted in the diagrams of the right panel (b).
Microscopic examination of 4’,6-diamidino-2-phenylindole-stained preparations of DoHH2 and MCA cell at 48h after treatment with 5mM nutlin-3a
showed morphologic evidence of apoptosis, including nuclear condensation and fragmentation, whereas no such changes were observed in nutlin-3a-
treated Pfeiffer and MS cells. (c) Western blot analysis of DLBCL cells with wt p53 after treatment with nutlin-3a showed increased levels of the
proapoptotic proteins BAX and PUMA in all cell lines with wt p53, known transcriptional targets of p53. Also, substantially decreased levels of BCL-XL
levels were observed after nutlin-3a treatment in DoHH2, OCI-LY10 and MCA cells, without much change in OCI-LY3 and EJ cells. Whereas the levels
of total BCL2 remained constant, the
p-Ser70BCL2 levels decreased dramatically after nutlin-3a treatment in all the cells with wt p53. In addition, western
blot analysis demonstrated cleavage of caspase-3, accompanied by activation of caspase-9. By contrast, no signiﬁcant changes in the levels of
proapoptotic or antiapoptotic proteins, or in activation of caspase-3 or -9, were observed in nutlin-3a-treated Pfeiffer and MS cells. Lysates were
prepared at 24h following nutlin-3a treatment. (d) Coimmunoprecepitation of DoHH2 and MCA cell lysates treated with 10mM of nutlin-3a or control
(dimethyl sulfoxide) showed that nutlin-3a induced binding of BCL2 by p53 protein, suggesting that non-transcriptional mechanisms are also involved
in nutlin-3a-induced cell death of t(14;18)-positive DLBCL cells. (e) Preincubation of DoHH2 and MCA cells with 25mM piﬁthrin-a (PFT-a)o r4 . 8mM
PFT-m (the maximum non-toxic dose) rescued a substantial number of nutlin-3a-treated cells from apoptotic cell death. PFT-m, an agent that inhibits the
interaction of p53 with antiapoptotic proteins without affecting p53 transactivation function, rescued a greater proportion of nutlin-3a-treatedD o H H 2
cells and a smaller proportion of MCA cells, whereas PFT-a rescued a larger proportion of nutlin-3a-treated-MCA cells and a smaller proportion of
DoHH2 cells. (f) Treatment with a comparatively small dose of nutlin-3a (1mM) enhanced dramatically the cytotoxicity of YC-137, a BH3 mimetic in
DoHH2 and MCA cells, with no effect observed in Pfeiffer and MS cells. Combined treatment with nutlin-3a and YC-137 synergistically induced
decreased viability of DoHH2 and MCA cells (average combination index (CI)¼0.53 and CI¼0.35, respectively).
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Leukemianutlin-3a-mediated activation of the p53 pathway (Figure 5b).
Immunohistochemical analysis of these tumors showed that the
mean proliferation index (Ki-67) was 92.8 and 75.4%, and
the percentage of p21-positive lymphoma cells was 13.8 and
42.3% in the control and treated groups, respectively (Po0.05,
Mann–Whitney U-test). Also, the average apoptotic index,
assessed by TUNEL, was 3.1 and 16.6%, and the percentage
of activated caspase-3-positive lymphoma cells was 2.1 and
15.7% in the control and treated groups, respectively (Po0.05,
Mann–Whitney U-test; Figure 5c). In aggregate, these results
support the interpretation that nutlin-3a treatment induces
p53-mediated cell cycle arrest and apoptosis in t(14;18)-positive
DLBCL cells in vivo.
Discussion
Molecules such as nutlin-3a that disrupt the p53–MDM2
interaction and activate the p53 pathway affect normal and
neoplastic cells differently. In normal cells, nutlin-3a predomi-
nantly induces reversible biological effects including cell
cycle arrest. In cancer cells with wt p53, on the other hand,
nutlin-3a additionally induces irreversible apoptosis, but in a
highly variable manner.
9,36 One hypothesis put forward to
explain this highly heterogeneous apoptotic response is that a
deﬁnite downstream block of the apoptotic machinery may be
involved in unresponsive cells.
9 We show here, using as a
paradigm wt p53 DLBCL cells that carry t(14;18)(q32;q21) and
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Figure 4 Nutlin-3a enhances the antitumor activity of chemotherapeutic agents against diffuse large B-cell lymphoma cells harboring wild-type
or mutant (mt) p53.( a) Combined treatment for 48h with nutlin-3a and doxorubicin synergistically inhibited the growth of DoHH2 and MCA cells
(average combination index (CI)¼0.34 and CI¼0.29, respectively). (b) Treatment with 10mM nutlin-3a for 48h enhanced the inhibitory effect of
0.5mM doxorubicin treatment by 50 and 60% on the growth of MS and Pfeiffer cells, respectively, and substantially decreased the cell viability by
34 and 50%, respectively. Nutlin-3a treatment, by itself, had no effect on the growth and survival of these cells (upper panel). Western blot analysis
showed that combined treatment of nutlin-3a and doxorubicin induced increased levels of the p53-related protein p73a in both MS and Pfeiffer
cells that harbor mt p53 (lower panel).
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Figure 5 Nutlin-3a inhibits the growth of t(14;18)-positive diffuse large B-cell lymphoma tumors with wild-type p 5 3i nv i v o .(a) Severe combined
immunodeﬁciency–Beige mice with already established (palpable) subcutaneous DoHH2 lymphomas were treated daily with nutlin-3a or vehicle for
2 weeks, and tumor volume was recorded. Error bars show s.d. from the mean. At the end of treatment, the average tumor volume in the control group
was 1965.5mm
3, whereas in the nutlin-3a-treated group, the average tumor volume was 107.5mm
3 (*Po0.02, Mann–Whitney U-test). Inset shows the
subcutaneous tumors (arrows). (b) Western blot analysis of six tumors after three injections showed upregulation of p53 and the p53 transcriptional targets
p21 and MDM2 speciﬁcally in the nutlin-3a-treated tumors, verifying nutlin-3a-mediated activation of the p53 pathway. (c) Immunohistochemical
analysis of tumors showed that the proliferation index (Ki-67) was 92.8 and 75.4%, and the percentage of p21-positive tumor cells was 13.8 and 42.3% in
the control and treated groups, respectively (Po0.05, Mann–Whitney U-test), supporting p53-mediated cell cycle arrest of the lymphoma cells. Also, the
apoptotic index assessed by TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) was 3.1 and 16.6%, and the percentage of activated
caspase-3-positive lymphoma cells was 2.1 and 15.7% in the control and treated groups, respectively (Po0.05, Mann–Whitney U-test), verifying the
ability of nutlin-3a to induce apoptosis in t(14;18)-positive diffuse large B-cell lymphoma cells in vivo. Hematoxylin and eosin and p53 immunostaining
of the tumors are also shown in the upper two rows (DAB as chromogen and hematoxylin as counterstain, original magniﬁcation  400).
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Leukemiaoverexpress BCL2, that isolated overexpression of BCL2 in this
context cannot impede the execution of the p53-mediated
apoptotic program. Because t(14;18)(q32;q21) and BCL2 over-
expression are regarded as an initiating oncogenic event in FL,
and also seem to have a deﬁnite role in the pathogenesis of a
subset of DLBCL tumors, our data provide further evidence that
nutlin-3a-induced activation of the p53 pathway may overcome
initiating oncogenic events, unrelated to the p53 pathway, in
agreement with data from recent studies.
1,6,40
These results also shed some light on the ﬁndings of a recent
study examining the in vivo biologic effects of low-dose
irradiation in FL cells.
41 Activation of the p53 pathway, induced
in this context by irradiation-induced DNA damage, was found
to result in cell cycle arrest and massive apoptosis.
41 The
authors, surprised by the simultaneous detection of p53 pathway
activation and high expression of BCL2 in FL cells, as well as
immunological tissue activation, speculated that tissue micro-
environment changes, including immunological activation may
have a predominant role in the induction of apoptosis of BCL2-
overexpessing lymphoma cells.
41 Although the tissue micro-
environment may have an important role, our results provide
evidence that speciﬁc activation of the p53 pathway can
result in apoptosis overcoming the antiapoptotic effect of
overexpressed BCL2 in a cell-autonomous manner in B-cell
lymphoma cells characterized by t(14;18).
Nutlin-3a-induced apoptotic cell death of DLBCL associated
with t(14;18) was associated with various changes in the levels
of proapoptotic and antiapoptotic proteins involving the
intrinsic apoptotic pathway, including increased PUMA and
BAX and decreased BCL-XL, although the levels of BCL2
remained constant. Similar changes also have been reported
after nutlin-3a treatment of other types of hematopoietic neo-
plastic cells, including Hodgkin lymphoma, anaplastic large cell
lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia
and mantle cell lymphoma cells facilitating apoptotic cell
death.
10,12,18,20,42,43
In addition, we show that nutlin-3a-induced apoptosis of
t(14;18)-positive DLBCL cells was associated with decreased
levels of
p-Ser70BCL2 levels. Phosphorylation of multiple residues
in the ﬂexible loop regulatory region of BCL2, including
serine-70, is regulated by multiple kinase signaling pathways,
including MAPK and JNK, as well as by various phosphatases,
including PP2A, and has been shown to enhance the
antiapoptotic function of BCL2.
30 Also, it has been shown that
this phosphorylation decreases direct binding of BCL2 by
activated p53, inhibiting one of the central non-transcriptional
mechanisms of p53-mediated apoptotic death.
31 In our in vitro
system, we showed that nutlin-3a-induced apoptosis of DLBCL
cells involves transcriptional as well as non-transcriptional
mechanisms including direct binding of BCL2 by nutlin-3a-
activated p53, and therefore nutlin-3a-induced dephosphoryla-
tion of BCL2 may facilitate this phenomenon. The exact
mechanisms of nutlin-3a-induced dephosphorylation of BCL2
are uncertain. However, the fact that BCL2 is known to be
predominantly unphosphorylated in the G1 phase of the cell
cycle in combination with the nutlin-3a-induced G1 cell cycle
arrest may, in part, explain this ﬁnding.
44,45 Also, other
investigators have reported involvement of non-transcriptional
mechanisms in nutlin-3a-induced cell death in other hemato-
logic malignancies after activation of the p53 pathway, further
supporting our data.
10,11,46 In our in vitro system, transcriptional
and non-transcriptional p53-mediated mechanisms seemed to
act in concert, overcoming collectively the antiapoptotic
function of BCL2 as shown by previous studies.
47 However,
our data are in contrast with a recent study on chronic
lymphocytic leukemia suggesting an antagonistic relationship
between these two mechanisms.
46 It is possible that the exact
interrelationship of these mechanisms varies in different cell
types.
Recently, new pharmacological agents that directly target
mitochondria inducing activation of the apoptotic machinery
have been introduced in experimental therapeutics.
35 Prominent
among these agents are molecules that directly inhibit anti-
apoptotic proteins such as BCL2.
48 These agents are already
being tested in clinical trials of various cancer types including
hematologic malignancies.
49 We show here that nutlin-3a can
synergistically enhance the antitumor effect of such agents,
augmenting their therapeutic potential. Other studies have
shown that a combination of nutlin-3a with BCL2 inhibitors
can result in synergistically enhanced apoptosis in acute
myeloid leukemia.
45,50 These ﬁndings further support our data.
Recent studies have shown that high concentrations of nutlin-
3a can induce an antitumor effect in cases of non-functional and
mt p53, partly, through activation of other partners of MDM2,
including p73 or E2F1, depending on the particular cell
context.
38,39 Accordingly, we have shown that nutlin-3a can
enhance the cytotoxicity of classical chemotherapeutic agents
against DLBCL cells associated with t(14;18) and mutated p53
associated with increased p73 expression. Our data are further
supported by recent studies showing that nutlin-3a can induce
increased expression of p73 in anaplastic large cell lymphoma
or mantle cell lymphoma cells harboring mt p53, and synergize
with chemotherapy for enhanced antitumor activity.
20,43 As p53
mutation can be associated with progression of FL to DLBCL,
our data suggest that nutlin-3a combined with classical
chemotherapy could be an experimental therapeutic strategy
in this context.
1,22,23 Also, the results of our in vivo animal study
show that nutlin-3a treatment was well tolerated by the animals
and exhibited signiﬁcant antitumor activity against DLBCL.
Previous in vivo animal studies also have shown that nutlin-3a
treatment has minimal side effects.
8,9,14 In addition, Mohammad
et al.
51 have employed a different small molecule MDM2-
inhibitor and a different animal model with FL and showed
extended survival of the treated animals.
51 These data further are
in accord with our ﬁndings.
In conclusion, our data suggest that inhibition of the
p53–MDM2 interaction by nutlin-3a can activate the p53
pathway, resulting in cell cycle arrest and apoptosis in DLBCL
cells with t(14;18)(q32;q21) and functional p53, and that nutlin-
3a can enhance the efﬁcacy of chemotherapy in cases with wt
or mutated p53. Therefore, agents like nutlin-3a targeting the
p53–MDM2 interaction may be valuable additions to novel
therapeutic strategies for patients with B-cell lymphomas
characterized by t(14;18)(q32;q21) and BCL2 overexpression.
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